维普期刊资源整合服务平台（V6.5）

149篇 您的检索式：作者名="Ratain"

选中清除导出查看参考文献查看引证文献引用追踪共8页首页上一页第1页下一页末页 /8 跳转

	题名	作者	年代	出处	被引量
1	Statistical and ethical issues in the design and conduct of phase Ⅰ and Ⅱ clinical trial of new anticancer agents 显示文摘	RATAIN MJ MICK R SCHDSKY RL	1993	J Natl Cancer Inst1993，85，7：	1
2	Anticancer drug discovery and development throughout the world 显示文摘	Schwartsmann G Ratain M J Cragg GM	2002	J Clin Oncol2002，20，：	1
3	Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials 显示文摘	Gray SW Hlubocky FJ Ratain MJ	2007	Journal of Clinical Oncology2007，25，23：	1
4	Phase II studies of modem drugs directed against new targets: If you are fazed, too, then resist RECIST 显示文摘	Ratain M J Eckhardt SG	2004	J Clin Oncol2004，22，22：	1
5	Phase II studies of modem drugs directed against new targets: if you are fazed, too, then resist RECIST显示文摘	Ratain Ml Eckhardt SG	2004	1 Clin Oneol2004，22，22：	1
6	Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma 显示文摘	Ratain M J Eisen T Stadler WM	2006	J Clin Oncol2006，24，16：	1
7	Final findings from a phase Ⅱ, placebo-controlled, randomized discontinuatoin trial (RDT) of Sorafenib (Bay 43 - 9006) in patients with advanced renal cell carcinoma (RCC)(abstract) 显示文摘	Ratain MJ Eisen T Stadler WM	2005	J Clin Oncol2005，23，16：	1
8	Phase Ⅱ placebo-controlled randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)显示文摘	Ratain MJ Eisen T Stadler WM	2006	Clin Oncol2006，24，16：	1
9	Phase Ⅱ placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma 显示文摘	Ratain M J Eisen T Stadler WM	2006	J Clin Oncol2006，24，16：	1
10	Phase Ⅰ clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer显示文摘	Schilsky RL Hohneker J Ratain MJ	1998	J Clin Oncol1998，16，4：	1
11	Pharmacogenetics and pharmacogenomics of anticancer agents 显示文摘	Huang RS Ratain MJ	2009	CA Cancer J Clin2009，59，1：	1
12	Interactions between MDM2 and TP53 Genetic Alterations,and Their Impact on Response to MDM2 Inhibitors andOther Chemotherapeutic Drugs in Cancer Cells显示文摘	Liu W He L Ramirez J Ratain M J	2009	Clin Cancer Res2009，15，24：	1
13	Clinical pharmacology of camptothecins显示文摘	Iyer L Ratain M J	1998	Cancer Chemother Pharmacol1998，，：	1
14	Phase Ⅱ placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma显示文摘	Ratain MJ Eisen T Stadler WM	2006	J Clin Oncol2006，24，16：	1
15	Laboratory and clinical studies of biochemical modulation by hydroxyurea 显示文摘	Schisky RL Ratain MJ Vokes EE	1992	Semin Oncol1992，19，39：	1
16	Pharmacogenetics:a tool for individualizing antineoplastic therapy显示文摘	Innocenti F Iyer L Ratain MJ	2000	Clin Pharmacokinet2000，39，5：	1
17	Irinotecan treatments in cancer patients with UGT1A1 polymorphisms显示文摘	Innocenti F Ratain MJ	2003	Oncology2003，17，5：	1
18	UGT pharmacogenomics: implications for cancer risk and cancer therapeutics显示文摘	Desai AA Innocenti F Ratain MJ	2003	Pharmacogenetics2003，13，8：	1
19	Phase II placebo-controlled randomized discontinuation trial of sorafenib in patientswithmetastatic renal cell carcinoma显示文摘	Ratain MJ Eisen T Stadler WM	2006	J Clin Oncol2006，24，：	1
20	Irinotecan dosing: does the CPT in CPT-11 stand for 'Can't Predict Toxicity'? 显示文摘	Ratain MJ	2002	J Clin Oncol2002，20，1：	1

返回顶部每页显示：

共8页首页上一页第1页下一页末页 /8 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示